Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05771402

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Sponsor: Chongqing Three Gorges Central Hospital

Conditions Anti-PD-1 Antibody Chronic Hepatitis b Peg-IFNα

Interventions Anti-PD-1 antibody NAs Peg-IFNα

Updated 6 times since 2023 Last updated: Sep 4, 2025 Started: Oct 10, 2023 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05771402, this PHASE2 trial focuses on Anti-PD-1 Antibody and Chronic Hepatitis b and remains actively recruiting participants. Sponsored by Chongqing Three Gorges Central Hospital, it has been updated 6 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE2

Status: Unknown → Recruiting · Phase: PHASE4 → PHASE2
Mar 2025 — Oct 2025 [monthly]

Unknown PHASE4

Status: Not Yet Recruiting → Unknown
Sep 2024 — Mar 2025 [monthly]

Not Yet Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE4
May 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE4

▶ Show 1 earlier version

Apr 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chongqing Three Gorges Central Hospital
First Affiliated Hospital of Chongqing Medical University
Guizhou Provincial People's Hospital
The Affiliated Hospital Of Southwest Medical University
The Second Affiliated Hospital of Chongqing Medical University

Data source: The Second Affiliated Hospital of Chongqing Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chongqing, China